Detalhe da pesquisa
1.
HER2 missense mutations have distinct effects on oncogenic signaling and migration.
Proc Natl Acad Sci U S A
; 112(45): E6205-14, 2015 Nov 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-26508629
2.
The juxtamembrane region of the EGF receptor functions as an activation domain.
Mol Cell
; 34(6): 641-51, 2009 Jun 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-19560417
3.
Mechanism for activation of mutated epidermal growth factor receptors in lung cancer.
Proc Natl Acad Sci U S A
; 110(38): E3595-604, 2013 Sep 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-24019492
4.
Structure-function analysis of oncogenic EGFR Kinase Domain Duplication reveals insights into activation and a potential approach for therapeutic targeting.
Nat Commun
; 12(1): 1382, 2021 03 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33654076
5.
Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers.
Cancer Cell
; 37(2): 183-199.e5, 2020 02 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31978326
6.
An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression.
J Natl Cancer Inst
; 109(11)2017 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29059433
7.
EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib.
Cancer Discov
; 5(11): 1155-63, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26286086
8.
LYN-activating mutations mediate antiestrogen resistance in estrogen receptor-positive breast cancer.
J Clin Invest
; 124(12): 5490-502, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-25401474
9.
Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer.
Nat Med
; 20(9): 1027-34, 2014 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-25173427
10.
AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.
Cancer Discov
; 4(9): 1046-61, 2014 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-24893891
11.
Maximizing the benefits of off-target kinase inhibitor activity.
Cancer Discov
; 3(2): 138-40, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-23400472
12.
EpCAM: another surface-to-nucleus missile.
Cancer Cell
; 15(3): 165-6, 2009 Mar 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-19249674
13.
Functional effects of glycosylation at Asn-579 of the epidermal growth factor receptor.
Biochemistry
; 44(45): 14920-31, 2005 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-16274239